Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Extreme obesity—also referred to as severe, grade III, or morbid obesity—is defined as a
body mass index (BMI)> 40 kg/m2, and occurs in 7.7% of the adult US population. 1 This …

The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin
remains uncertain in obese patients. We assessed the comparative effectiveness and safety …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …